ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
ABVCABVC BioPharma(ABVC) Newsfilter·2024-04-10 20:30

ABVC BioPharma, Inc.许可协议 - ABVC BioPharma, Inc.与其附属公司BioLite, Inc.和Rgene Corporation与OncoX BioPharma, Inc.签署了一项潜在的具有突破性意义的许可协议[1] - ABVC将获得5000万美元的许可费用，并在首次筹款轮后再获得500万美元的里程碑付款[2] ABVC产品管道潜力 - ABVC的产品管道在全球癌症治疗市场具有巨大潜力，预计到2032年市值将达到约3936.1亿美元[8]